ClinicalTrials.gg
CompletedNCT00289991IMPROVITUpdated Nov 20, 2015Results posted

Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

A Phase 3 interventional study of Itraconazole and Vfend - voriconazole in Antifungal Prophylaxis of Invasive Fungal Infections, sponsored by Pfizer. Completed at 49 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-11-20.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
489
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Invasive Fungal Infections with a site in United Kingdom — none open to participants now, none under way, none of them phase 3. Invasive Fungal Infections · United Kingdom.

Started
2006
the only one that year
Phase 3
5 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Pfizer

Among the 10 studies in Invasive Fungal Infections with a site in United Kingdom, this one is the only one that started in 2006, is one of 5 in phase 3, and was the 2nd registered.

Invasive Fungal Infections

136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.

Browse Invasive Fungal Infections studies →

Open to participants now

None of the 10 studies in Invasive Fungal Infections with a site in United Kingdom is open now. The open studies under Invasive Fungal Infections, anywhere →

Who these studies take

Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Invasive Fungal Infections with a site in United Kingdom as a file.
02

Study summary

Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.

03

Conditions studied

  • Antifungal Prophylaxis of Invasive Fungal Infections
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HSCT for acute leukemia (AML, ALL or myelodysplastic syndrome) failed lymphoma therapy or transformation of CML
  • Male and Female over 12 years or greater

Exclusion criteria

Exclusion Criteria:

  • Possible, probable or proven IFI at study entry or at any time in 6 months prior to study entry, defined according to the 'consensus criteria' (Ascioglu et al 2002)
  • Previous history of zygomycosis
  • Anticipated survival less than one month
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
489 participants (actual)

Study arms

  • Active comparator
    Itraconazole

    Drug: Itraconazole

  • Experimental
    Voriconazole

    Drug: Vfend - voriconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Success at Day 180: Percent of Responders (Randomization Strata)

    Percent of responders (by randomization strata) with success of antifungal prophylaxis at 180 days after allogeneic hematopoietic stem cell transplant (HSCT). Success: alive at Day 180 (Visit 9), had not developed a breakthrough proven or probable invasive fungal infection (IFI) by Visit 9, and received full course of study drug prophylaxis without interruption of greater than 14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 9, imputed as failure at Visit 9 (programmatically).

    Time frame: Day 180 (Visit 9)

Secondary outcomes

  1. Success at Day 100: Percent of Responders (Randomization Strata)

    Percent of responders (by randomization strata) with success of antifungal prophylaxis at 100 days after allogeneic HSCT. Success defined as: alive at Day 100 (Visit 7), had not developed a breakthrough proven or probable IFI by Visit 7, and received full course of study drug prophylaxis without an interruption of \>14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 7, imputed as failure at Visit 7 (programmatically).

    Time frame: Day 100 (Visit 7)

  2. Time to Breakthrough Invasive Fungal Infection (IFI)

    Summary of time (in days) from start of prophylaxis to first recorded occurrence of breakthrough proven or probable IFI.

    Time frame: Day 1 up to Day 180 (Visit 9)

  3. Percent of Subjects With Occurrence of Breakthrough IFI

    Percent of subjects with occurrence of breakthrough IFI (proven or probable). Included all subjects in the MITT population.

    Time frame: Day 1 up to Day 100 (Visit 7) and Day 180 (Visit 9)

  4. Survival: Percent of Subjects Who Died at or Before Day 180

    Percent of subjects who died at or before Day 180, derived from the crude death rate. All subjects in the MITT population included in this proportion.

    Time frame: Day 1 up to Day 180 (Visit 9)

  5. Time to Discontinuation of Study Treatment

    Time in days to discontinuation of study treatment defined as the number of days from first dose to last dose inclusive as recorded in the dosing log.

    Time frame: Day 1 up to Day 180 (Visit 9)

  6. Survival: Percent of Subjects Who Died Within 1 Year

    Percent of subjects who died within 1 year after transplant, derived from the crude death rate. All subjects in the MITT population included in this proportion. Only deaths up until and including 365 days after first dose of study medication included in the analysis.

    Time frame: Day 1 up to 1 year (Day 365)

  7. Duration of Treatment

    Median duration in days of treatment. Treatment is defined as the total number of days on which subjects took medication.

    Time frame: Day 1 up to Day 180

  8. Percent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment

    Percent of subjects who used other systemic antifungal agents as empirical or therapeutic treatment, defined as either empirical: subject took a systemic antifungal agent at any time after the day of first dose of medication and did not develop a breakthrough proven or probable IFI during the study or therapeutic: subject developed a breakthrough proven or probable IFI.

    Time frame: Day 1 up to Day 180

07

Results

Posted Mar 10, 2010
Limitations and caveats
Data was excluded from 1 site due to Good Clinical Practices deviations.

Participant flow

Participant flow — Overall Study
MilestoneVoriconazoleItraconazole
Started234255
Completed176175
Not completed5880
Withdrew: Death3538
Withdrew: Adverse event1513
Withdrew: Failure of prophylaxis11
Withdrew: Fungal breakthrough infection01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject212
Withdrew: Other514

Outcome measures

PrimarySuccess at Day 180: Percent of Responders (Randomization Strata)

Percent of responders (by randomization strata) with success of antifungal prophylaxis at 180 days after allogeneic hematopoietic stem cell transplant (HSCT). Success: alive at Day 180 (Visit 9), had not developed a breakthrough proven or probable invasive fungal infection (IFI) by Visit 9, and received full course of study drug prophylaxis without interruption of greater than 14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 9, imputed as failure at Visit 9 (programmatically).

Time frame:
Day 180 (Visit 9)
Reported as:
Number · percent of participants
Success at Day 180: Percent of Responders (Randomization Strata)
percent of participantsVoriconazoleItraconazole
Myeloablative/matched related (n=66, 85)59.144.7
Myeloablative/mismatched unrelated (n=59, 58)52.525.9
Non-myeloablative/matched related (n=58, 57)34.528.1
Non-myeloablative/mismatched unrelated (n=41, 41)46.326.8
Statistical analysis
  • Voriconazole vs Itraconazole · Difference in adjusted responder rates · Percent difference adjusted proportions: 16.4 · 95% CI 7.7 to 25.1Overall treatment difference in adjusted proportions (expressed as percentages) calculated using Fleiss method.
SecondarySuccess at Day 100: Percent of Responders (Randomization Strata)

Percent of responders (by randomization strata) with success of antifungal prophylaxis at 100 days after allogeneic HSCT. Success defined as: alive at Day 100 (Visit 7), had not developed a breakthrough proven or probable IFI by Visit 7, and received full course of study drug prophylaxis without an interruption of \>14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 7, imputed as failure at Visit 7 (programmatically).

Time frame:
Day 100 (Visit 7)
Reported as:
Number · percent of participants
Success at Day 100: Percent of Responders (Randomization Strata)
percent of participantsVoriconazoleItraconazole
Myeloablative/matched related (n=66, 85)65.250.6
Myeloablative/mismatched unrelated (n=59, 58)55.927.6
Non-myeloablative/matched related (n=58, 57)43.138.6
Non-myeloablative/mismatched unrelated (n=41, 41)48.836.6
Statistical analysis
  • Voriconazole vs Itraconazole · Difference in adjusted responder rates · Percent difference adjusted proportions: 15.4 · 95% CI 6.6 to 24.2Overall treatment difference in adjusted proportions (expressed as percentages) calculated using Fleiss method.
SecondaryTime to Breakthrough Invasive Fungal Infection (IFI)

Summary of time (in days) from start of prophylaxis to first recorded occurrence of breakthrough proven or probable IFI.

Time frame:
Day 1 up to Day 180 (Visit 9)
Reported as:
Mean · days
Time to Breakthrough Invasive Fungal Infection (IFI)
daysVoriconazoleItraconazole
Time to Breakthrough Invasive Fungal Infection (IFI)119.0 ± 28.5877.0 ± 77.08
SecondaryPercent of Subjects With Occurrence of Breakthrough IFI

Percent of subjects with occurrence of breakthrough IFI (proven or probable). Included all subjects in the MITT population.

Time frame:
Day 1 up to Day 100 (Visit 7) and Day 180 (Visit 9)
Reported as:
Number · percent of participants
Percent of Subjects With Occurrence of Breakthrough IFI
percent of participantsVoriconazoleItraconazole
Day 1000.91.2
Day 1801.31.7
Statistical analysis
  • Voriconazole vs Itraconazole · Difference in proportions · p = 0.7114 · Difference in proportions: percent: -0.4 · 95% CI -2.2 to 1.5Approximate 2-sided 95 percent (%) confidence interval for the difference in proportions.
  • Voriconazole vs Itraconazole · Difference in proportions · p = 0.7759 · Difference in proportion: percent: -0.3 · 95% CI -2.5 to 1.9Approximate 2-sided 95 percent (%) confidence interval for the difference in proportions.
SecondarySurvival: Percent of Subjects Who Died at or Before Day 180

Percent of subjects who died at or before Day 180, derived from the crude death rate. All subjects in the MITT population included in this proportion.

Time frame:
Day 1 up to Day 180 (Visit 9)
Reported as:
Number · percent of participants
Survival: Percent of Subjects Who Died at or Before Day 180
percent of participantsVoriconazoleItraconazole
Survival: Percent of Subjects Who Died at or Before Day 18015.615.4
Statistical analysis
  • Voriconazole vs Itraconazole · Difference in proportions · Difference in proportions: percent: 0.3 · 95% CI -6.3 to 6.9Approximate 2-sided 95% confidence interval for the difference in proportions.
SecondaryTime to Discontinuation of Study Treatment

Time in days to discontinuation of study treatment defined as the number of days from first dose to last dose inclusive as recorded in the dosing log.

Time frame:
Day 1 up to Day 180 (Visit 9)
Reported as:
Mean · days
Time to Discontinuation of Study Treatment
daysVoriconazoleItraconazole
Time to Discontinuation of Study Treatment88.7 ± 61.4171.5 ± 52.21
Statistical analysis
  • Voriconazole vs Itraconazole · Wilcoxon (Mann-Whitney) · p = 0.00262-sided Wilcoxon (Mann-Whitney)
SecondarySurvival: Percent of Subjects Who Died Within 1 Year

Percent of subjects who died within 1 year after transplant, derived from the crude death rate. All subjects in the MITT population included in this proportion. Only deaths up until and including 365 days after first dose of study medication included in the analysis.

Time frame:
Day 1 up to 1 year (Day 365)
Reported as:
Number · percent of participants
Survival: Percent of Subjects Who Died Within 1 Year
percent of participantsVoriconazoleItraconazole
Survival: Percent of Subjects Who Died Within 1 Year25.930.7
Statistical analysis
  • Voriconazole vs Itraconazole · Difference in proportions · p = 0.2487 · Difference in proportions: percent: -4.8 · 95% CI -13.0 to 3.4Approximate 2-sided 95 percent % confidence interval for the difference in proportions.
SecondaryDuration of Treatment

Median duration in days of treatment. Treatment is defined as the total number of days on which subjects took medication.

Time frame:
Day 1 up to Day 180
Reported as:
Median · days
Duration of Treatment
daysVoriconazoleItraconazole
Duration of Treatment96.0 (1 to 258)68.0 (3 to 223)
SecondaryPercent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment

Percent of subjects who used other systemic antifungal agents as empirical or therapeutic treatment, defined as either empirical: subject took a systemic antifungal agent at any time after the day of first dose of medication and did not develop a breakthrough proven or probable IFI during the study or therapeutic: subject developed a breakthrough proven or probable IFI.

Time frame:
Day 1 up to Day 180
Reported as:
Number · percent of participants
Percent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment
percent of participantsVoriconazoleItraconazole
Percent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment40.649.4
Statistical analysis
  • Voriconazole vs Itraconazole · Difference in proportions · p = 0.0570 · Difference in proportions: percent: -8.8 · 95% CI -17.8 to 0.3Approximate 2-sided 95% confidence interval for the difference in proportions.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voriconazole—111/234 (47.4%)228/234 (97.4%)
Itraconazole—95/255 (37.3%)252/255 (98.8%)
Most frequent serious events
Showing 10 of 196
Most frequent serious events
EventVoriconazoleItraconazole
PyrexiaGeneral disorders19/23411/255
Cytomegalovirus infectionInfections and infestations9/23411/255
Graft versus host diseaseImmune system disorders9/2348/255
DiarrhoeaGastrointestinal disorders8/2349/255
VomitingGastrointestinal disorders1/2347/255
Acute graft versus host diseaseImmune system disorders2/2347/255
NauseaGastrointestinal disorders2/2346/255
Acute graft versus host disease in intestineImmune system disorders5/2346/255
Cystitis haemorrhagicRenal and urinary disorders3/2346/255
Acute graft versus host disease in liverImmune system disorders5/2341/255
Most frequent other events
Showing 10 of 71
Most frequent other events
EventVoriconazoleItraconazole
Mucosal inflammationGeneral disorders115/234142/255
DiarrhoeaGastrointestinal disorders100/234132/255
PyrexiaGeneral disorders105/234101/255
VomitingGastrointestinal disorders78/234103/255
NauseaGastrointestinal disorders86/23491/255
HeadacheNervous system disorders63/23469/255
Febrile neutropeniaBlood and lymphatic system disorders51/23468/255
RashSkin and subcutaneous tissue disorders48/23445/255
Abdominal painGastrointestinal disorders45/23450/255
CoughRespiratory, thoracic and mediastinal disorders45/23442/255

Baseline characteristics

Age, Customized
Age, Customized(participants)VoriconazoleItraconazoleTotal
<18 years91120
Between 18 and 44 years106119225
Between 45 and 64 years104115219
>=65 years151025
Age, Continuous
Age, Continuous(years)VoriconazoleItraconazoleTotal
Mean43.3 ± 14.442.7 ± 14.643.0 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)VoriconazoleItraconazoleTotal
Female96100196
Male138155293
08

Study locations

49 sites
  • Pfizer Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Bmo, 625 00, Czech Republic
  • Pfizer Investigational Site
    Praha, 128 20, Czech Republic
  • Pfizer Investigational Site
    Cairo, Egypt
  • Pfizer Investigational Site
    Marseille, Cedex 09 13273, France
  • Pfizer Investigational Site
    Caen, 14033, France
  • Pfizer Investigational Site
    Creteil, 94010, France
  • Pfizer Investigational Site
    Paris, 75475, France
  • Pfizer Investigational Site
    Pessac, 33600, France
  • Pfizer Investigational Site
    Rouen Cedex, 76038, France
  • Pfizer Investigational Site
    Vandoeuvre Les Nancy Cedex, 54511, France
  • Pfizer Investigational Site
    Villejuif, 94805, France
  • Pfizer Investigational Site
    Exohi Asvestohoriou, Thessaloniki 57010, Greece
  • Pfizer Investigational Site
    Athens, 11527, Greece
  • Pfizer Investigational Site
    Amman, Jordan
  • Pfizer Investigational Site
    Lisboa, 1099-023, Portugal
  • Pfizer Investigational Site
    Porto, 4200-072, Portugal
  • Pfizer Investigational Site
    Moscow, 117997, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 197089, Russian Federation
  • Pfizer Investigational Site
    Badalona, Barcelona 08916, Spain
  • Pfizer Investigational Site
    Barcelona, 08025, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Madrid, 28006, Spain
  • Pfizer Investigational Site
    Madrid, 28034, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Salamanca, 37007, Spain
  • Pfizer Investigational Site
    Sevilla, 41013, Spain
  • Pfizer Investigational Site
    Valencia, 46009, Spain
  • Pfizer Investigational Site
    Valencia, 46010, Spain
  • Pfizer Investigational Site
    CH-4031 Basel, Switzerland
  • Pfizer Investigational Site
    Geneve, CH-1211, Switzerland
  • Pfizer Investigational Site
    Ankara, 06590, Turkey
  • Pfizer Investigational Site
    Kayseri, 38039, Turkey
  • Pfizer Investigational Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Pfizer Investigational Site
    Bristol, BS2 8BL, United Kingdom
  • Pfizer Investigational Site
    Cambridge, CB2 2QQ, United Kingdom
  • Pfizer Investigational Site
    Cardiff, CF14 4XW, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G12 0YN, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G4 0SF, United Kingdom
  • Pfizer Investigational Site
    Leeds, LS9-7TF, United Kingdom
  • Pfizer Investigational Site
    Leicester, LW1 5WW, United Kingdom
  • Pfizer Investigational Site
    London, Nw3 2qg, United Kingdom
  • Pfizer Investigational Site
    London, SE1 9RT, United Kingdom
  • Pfizer Investigational Site
    London, SE5 9RS, United Kingdom
  • Pfizer Investigational Site
    Manchester, M20 4BX, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2006
First posted
Feb 10, 2006
Start
Mar 2006
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Mar 10, 2010
Last update
Nov 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00289991
Lead sponsor
Pfizer
First posted
Feb 10, 2006
Start date
Mar 2006
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Mar 10, 2010
Last update
Nov 20, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion